Evidence map›Paper›PMID 28978127›Full record

ArticleOncotarget2017

HIV-1 Gp120 clade B/C induces a GRP78 driven cytoprotective mechanism in astrocytoma.

Sheila N López, Madeline Rodríguez-Valentín, Mariela Rivera, Maridaliz Rodríguez, Mohan Babu, Luis A Cubano, Huangui Xiong, Guangdi Wang, Lilia Kucheryavykh, Nawal M Boukli

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.1field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. HIV-1 gp120-Induced Endolysosome de-Acidification Leads to Efflux of Endolysosome Iron, and Increases in Mitochondrial Iron and Reactive Oxygen Species.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2022
    Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Sheila N LópezBiomedical Proteomics Facility, Department of Microbiology and Immunology, Universidad Central del Caribe, School of Medicine, Bayamón, PR, USA.
Madeline Rodríguez-ValentínBiomedical Proteomics Facility, Department of Microbiology and Immunology, Universidad Central del Caribe, School of Medicine, Bayamón, PR, USA.
Mariela RiveraBiomedical Proteomics Facility, Department of Microbiology and Immunology, Universidad Central del Caribe, School of Medicine, Bayamón, PR, USA.
Maridaliz RodríguezBiomedical Proteomics Facility, Department of Microbiology and Immunology, Universidad Central del Caribe, School of Medicine, Bayamón, PR, USA.
Mohan BabuDepartment of Biochemistry, Research and Innovation Center, University of Regina, Saskatchewan, Canada.
Luis A CubanoBiomedical Proteomics Facility, Department of Microbiology and Immunology, Universidad Central del Caribe, School of Medicine, Bayamón, PR, USA.
Huangui XiongDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA.
Guangdi WangRCMI Cancer Research Center, Xavier University of Louisiana, New Orleans, LA, USA.
Lilia KucheryavykhDepartment of Biochemistry, Universidad Central del Caribe, School of Medicine, Bayamón, PR, USA.
Nawal M BoukliBiomedical Proteomics Facility, Department of Microbiology and Immunology, Universidad Central del Caribe, School of Medicine, Bayamón, PR, USA.
Central University of the Caribbean · PRUniversity of Nebraska Medical Center · USUniversity of Regina · CAXavier University of Louisiana · US

Funding

Xavier's RCMI Cancer Research ProgramG12MD007595 · NIMHD · XAVIER UNIVERSITY OF LOUISIANA · PI D'AMOUR, GENE, WANG, GUANGDI · 2012 to 2018
$15.7M
UNIVERSIDAD CENTRAL DEL CARIBE BIOMEDICAL RESEARCH CENTERSG12MD007583 · NIMHD · UNIVERSIDAD CENTRAL DEL CARIBE · PI FERNANDEZ, DIANA MARIA · 2012 to 2016
$8.4M
Microglial ion channels and HIV-1-associated dementiaR01NS077873 · NINDS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI XIONG, HUANGUI HANK · 2012 to 2016
$1.8M
NIMHD NIH HHS G12 MD007583NIMHD NIH HHS G12 MD007595NINDS NIH HHS R01 NS077873
6 · The paper itself

Abstract

HIV-1 clades are known to be one of the key factors implicated in modulating HIV-associated neurocognitive disorders. HIV-1 B and C clades account for the majority of HIV-1 infections, clade B being the most neuropathogenic. The mechanisms behind HIV-mediated neuropathogenesis remain the subject of active research. We hypothesized that HIV-1 gp120 clade B and C proteins may exert differential proliferation, cell survival and NeuroAIDS effects in human astrocytoma cells via the Unfolded Protein Response, an endoplasmic reticulum- based cytoprotective mechanism. The differential effect of gp120 clade B and C was evaluated using for the first time a Tandem Mass Tag isobaric labeling quantitative proteomic approach. Flow cytometry analyses were performed for cell cycle and cell death identification. Among the proteins differentiated by HIV-1 gp120 proteins figure cytoskeleton, oxidative stress, UPR markers and numerous glycolytic metabolism enzymes. Our results demonstrate that HIV-1 gp120 B induced migration, proliferative and protective responses granted by the expression of GRP78, while HIV-1 gp120 C induced the expression of key inflammatory and pro-apoptotic markers. These novel findings put forward the first evidence that GRP78 is a key player in HIV-1 clade B and C neuropathogenic discrepancies and can be used as a novel target for immunotherapies.

Indexed as

Gp120GRP78HIV-1 clades B and Cquantitative proteomics (tandem mass tag)unfolded protein response (UPR)

Identifiers

PMID28978127
PMCPMC5620267
OpenAlexW2736899128

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.